LivaNova is reinventing itself by shedding off parts that aren’t efficient and tightly focusing on building up its cardiac surgery and neuromodulation businesses.

These changes seem to be paying off for the London-based company. Earlier this week, LivaNova said sales for the fourth quarter of 2017 grew 11.5%. For the full year, LivaNova had earnings per share about $3.54, which beat consensus of $3.32.

“We were very pleased to exit 2017 with strong momentum and to make the financial commitments that we laid out for you from sales to earnings, LivaNova CEO Damien McDonald said, according to a transcript from Seeking Alpha. “We made significant advancements as the year progressed. Our foundation is solid, and we have an abundance of growth drivers to advance the business.”

Worldwide sales from continuing operations for the fourth quarter were $278.4 million, up 8.1 percent on a constant currency basis compared to the fourth quarter of 2016.

Don't miss the Advanced Design and Manufacturing Conference and Expo in Cleveland, March 7-8, 2018.  

In late 2017, LivaNova began embarking on the mantra of change. The London-based company announced it would divest its cardiac rhythm management (CRM) business to MicroPort for $190 million in cash in November.

“We believe this transaction will be favorable for all parties involved,” McDonald said. “For MicroPort, the transaction allows them to strengthen their global presence. For LivaNova, it allows us to focus on our areas of leadership and strength, cardiac surgery and neuromodulation. The deal is progressing well, and we are on track to close it in the second quarter.

Just two weeks after the CRM divestiture was announced, LivaNova revealed plans to acquire San Diego, CA-based ImThera for $225. ImThera would help boost the company’s neuromodulation offerings.

 Last month, LivaNova said it would acquire Pittsburgh, PA-based TandemLife for up to $250 million to bolster its cardiac surgery portfolio.

“Now turning to TandemLife; we like this deal for many reasons,” McDonald said. “This is another acquisition aligned with our strategy of adding products that complement our existing portfolio, in this case, Cardiac Surgery. TandemLife created products to be simple enough to set up and deploy in a broad range of hospitals, and it is the only company with a complete set of system solutions that can be used for all applications, from Extracorporeal Life Support, or ECLS, to continuous mechanical circulatory support.”

LivaNova’s no stranger to change or mergers. The company was formed when Sorin and Cyberonics merged in 2015.